Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Adrenal Disorders
Does the imaging finding of central necrosis of an adrenal tumor, biochemically confirmed as pheochromocytoma, increase the risk of malignancy?
Related Questions
How do you manage patients who are positive for the 21-hydroxylase antibody but have no clinical or laboratory evidence of adrenal insufficiency?
Are there any differences in specificity or sensitivity of the ACTH stimulation test when cosyntropin is administered intravenously versus intramuscularly?
In patients with secondary adrenal insufficiency, when would you consider adding fludrocortisone to their steroid regimen?
When starting stress dose steroids for patient with primary adrenal insufficiency, how do you decide whether to start hydrocortisone 100 mg every 8 hours versus 50 mg every 6 hours?
How do you counsel patients on the likelihood of resolution of their hypertension post adrenalectomy for primary hyperaldosteronism?
What is the likelihood of recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients who develop immunotherapy induced adrenal insufficiency?
Do you recommend using a 24-hour urinary cortisol/urinary creatinine ratio over a 24 hour urine cortisol to screen patients for Cushing's syndrome?
Do you forgo adrenal imaging in a patient with primary hyperaldosteronism who has decided against surgery?
What is the role of oral therapy for hypercortisolism diagnosed based on unsuppressed cortisol after 1mg dexamethasone suppression test in a normoglycemic patient who also has negative adrenal imaging?
How will the newer JCEM guidelines on primary aldosteronism (PA) impact your management and screening of PA?
